Zota Health Care Ltd
Zota Health Care Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.
From Zota Health Care Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years.
- Gross margins have improved YoY from 55% to nearly 60%, driven by higher Davaindia revenue contribution.
- Blended EBITDA margin at consolidated level expected to improve to 15%-20% over 2-3 years if no new stores added, reflecting maturation of existing stores.
- Planned aggressive expansion with 800-1,000 new COCO stores annually; next year's store addition to be more evenly phased (~200-250 per quarter).
- Footfalls at mature stores rising (80-100 daily customers for >2 years stores), with overall footfall stable despite new low-traffic stores.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
- Majority of the funds are used for new store expansions and working capital requirements within Davaindia.
- A smaller portion of the QIP funds is allocated to General Corporate Purposes.
- The company has incorporated a new wholly owned subsidiary, KMHP Ventures Limited, to engage in marketing and trading of pharmaceutical products, enhancing control over sourcing, distribution, and margin optimization.
- Additional equity has been infused in Davaindia Health Mart Limited to support COCO store expansion and working capital.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Zota Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹163 Cr, net loss ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Zota Health Care Ltd Q3 FY26 results?
Mature stores in the first cohort (~4 years old) are growing at 15%-20% year-on-year, with revenues around INR7 lakh per month and potential to exceed INR1 crore per annum in 2 years. EBITDA margins are expected to improve significantly as stores mature; mature COCO stores can achieve EBITDA margins of 25%-30%, and overall company EBITDA margins could reach 15%-20% in 2-3 years if no new stores are added.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹3,918 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
The INR 350 crore raised through the QIP is primarily being deployed towards Davaindia.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.